A house divided cannot stand. Gerald and the BOD

A house divided cannot stand. Gerald and the BOD and BOA understand the need to build broad support from shareholders for the aforementioned amendments in preparation for up listing to a National Exchange. They know that shareholders, myself included, among many others, are going to be very hesitant to approve the amendments without substantial positive news regarding LYMPRO and or MANF, or both in the coming days and weeks. Because of the need to build consensus before that Sept. 22 meeting, I believe that we will see very substantive news on a number of fronts in the very near future. Regarding LYMPRO; projections for revenue; specificity numbers and perhaps an announcement of a JV or partnership for commercialization this fall. In regards to MANF we could hear that the Orphan indication has been applied for regarding RP, or perhaps with Wolfram’s instead. We could also hear of the initiation of Phase 2b with Eltoprazine and perhaps a MJFF grant to help get that study seriously rolling. Any number of these or others, could ignite a pyroclastic explosion of buyers propelling AMBS towards up listing to a National Exchange.....I am confident that the BOD and BOA in conference will have the needed ammunition to accomplish the mission. Stand by for ignition!